

Investigational Drug Service

University of California
San Francisco Medical Center-MB
1975 4th Street, Room C6984
San Francisco, CA 94158

Tel: 415/514-3875

University of California
San Francisco Medical Center-PN
505 Parnassus Avenue, Room M39-C
San Francisco, CA 94143

Tel: 415/353-1798

University of California
San Francisco Medical Center-PCMB
1825 4th Street, Room L3113
San Francisco, CA 94158

Tel: 415/502-4040

University of California
San Francisco Medical Center-Mt Zion
1600 Divisadero Street, Room A002
San Francisco, CA 941115

Tel: 415/353-7052

www.ucsfhealth.org

October 2, 2020

Re: Revised Investigational Drug Return Processing during COVID-19 Pandemic

Dear Investigators and Research Staff,

This memo supersedes the investigational drug return memo issued on 17MAR2020.

From the period of 17MAR2020 to date, investigational drug patient returns were not counted due to previous evidence suggesting SARS-COV-2 virus viability and detection on inanimate surfaces for up to 2-3 days. This data came from laboratory conditions. ¹

Recent evidence gathered from real-life studies determined that transmission of SARS-COV-2 from inanimate surfaces is unlikely to occur, provided that *standard cleaning procedures and precautions are enforced*. ²

Effective 05OCT2020, all UCSF IDS Pharmacy locations will resume our standard practice of counting and documenting patient investigational drug returns prior to drug destruction.

Kind Regards,



Maha Kadafour, PharmD, BCPS
Investigational Drug Service Pharmacy Manager
Department of Pharmaceutical Services
UCSF Health
Mobile: (415) 205-1387
Email: maha.kadafour@ucsf.edu

¹ van Doremalen, et al. Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. <https://www.medrxiv.org/content/10.1101/2020.03.09.20033217v1.full.pdf>

²Mondelli, M et al. Low risk of SARS-CoV-2 transmission by fomites in real-life conditions. <https://www.thelancet.com/action/showPdf?pii=S1473-3099%2820%2930678-2>. Accessed 02OCT2020.